Compare GANX & RFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GANX | RFM |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.6M | 89.3M |
| IPO Year | 2021 | 2019 |
| Metric | GANX | RFM |
|---|---|---|
| Price | $2.00 | $14.64 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $7.50 | N/A |
| AVG Volume (30 Days) | ★ 490.8K | 8.2K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.46 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $55,180.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.53 | $13.68 |
| 52 Week High | $4.34 | $15.03 |
| Indicator | GANX | RFM |
|---|---|---|
| Relative Strength Index (RSI) | 55.28 | 38.27 |
| Support Level | $1.64 | $14.07 |
| Resistance Level | $2.05 | $14.61 |
| Average True Range (ATR) | 0.13 | 0.16 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 47.18 | 5.56 |
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
RiverNorth Flexible Municipal Income Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is to seek current income exempt from regular U.S. federal income taxes. The fund's secondary investment objective is total return.